LOGIN  |  REGISTER
Cue Biopharma

Latest Collaboration News

Tempus AI Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma

February 13
Last Trade: 89.50 5.75 6.87

CHICAGO / Feb 13, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). The collaboration...Read more


Conduit Pharmaceuticals Partners with Charles River Laboratories in Clinically Relevant Systemic Lupus Erythematosus Model

February 13
Last Trade: 1.68 0.05 3.07

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River’s immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes. The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and...Read more


IDEAYA Biosciences Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

February 13
Last Trade: 21.00 0.24 1.16

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in MTAP-deletion NSCLC The potential first-in-class clinical combination of IDE397 and Trodelvy targets two mechanistically distinct and complementary nodes of MTAP-deletion in solid tumors MTAP-deletion prevalence in NSCLC is estimated to be...Read more


GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System

February 12
Last Trade: 55.02 2.44 4.64

GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience  MENLO PARK, Calif. and SECAUCUS, N.J., Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic...Read more


AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

February 12
Last Trade: 192.87 13.67 7.63

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...Read more


Royalty Pharma Announces R&D Funding Collaboration With Biogen

February 12
Last Trade: 32.36 -0.10 -0.31

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). “We are excited to...Read more


Bolt Biotherapeutics Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries

February 11
Last Trade: 0.50 -0.06 -10.20

Targeting Unmet Needs for Treating Solid Tumors REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The collaborators are developing a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple...Read more


Oragenics Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

February 11
Last Trade: 0.30 0.004 1.36

SARASOTA, Fla. and RICHMOND, Va., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain...Read more


Nasdaq-Listed Prenetics Global Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve

February 11
Last Trade: 5.41 0.32 6.29

CircleDNA powers blockchain-based identity verification with Humanity Protocol, valued at US $1.1bn after latest fundraise Prenetics invests $1.5M in Bitcoin, Solana and H tokens, supported by strong balance sheet Prenetics advances Decentralized Science (DeSci) with AI-driven early cancer detection, backed by $30M investment from Tencent CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a...Read more


Charles River Laboratories and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions

February 11
Last Trade: 151.99 -1.18 -0.77

WILMINGTON, Mass. & DUBLIN / Feb 11, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Deciphex, a leader in AI-powered digital pathology, today announced the next phase of a strategic collaboration to focus on advancing cutting-edge image management solutions, while continuing to develop novel artificial intelligence (AI) tools for toxicologic pathology. Together, Deciphex and Charles River will...Read more


Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

February 10
Last Trade: 19.95 0.84 4.40

PASADENA, Calif. / Feb 10, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary...Read more


Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

February 10
Last Trade: 1.13 0.06 5.61

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step...Read more


Predictive Oncology Partners with Switzerland-Based Tecan Group to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D Analysis

February 10
Last Trade: 1.62 0.14 9.46

Study used Predictive Oncology’s vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient tumor spheroids Results presented at the 2025 Society for Laboratory Automation and Screening (SLAS) PITTSBURGH, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from an ongoing...Read more


Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

February 7
Last Trade: 1.68 0.05 3.07

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT)...Read more


Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

February 6
Last Trade: 12.79 0.85 7.12

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function REDWOOD CITY, Calif. , Feb. 6, 2025 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology. CZI is...Read more


Dr. Reddy's Laboratories enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

February 6
Last Trade: 13.60 -0.39 -2.79

Dr. Reddy’s gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the U.S. and Europe HYDERABAD, India / Feb 06, 2025 / Business Wire / Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that it has entered...Read more


Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

February 6
Last Trade: 1.88 0.02 1.08

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial  Data presented at AACR 2023 supports dual-targeting potential of IMM-1-104 in combination with anti-PD-1  CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) --  Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize...Read more


Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

February 5
Last Trade: 14.56 -0.09 -0.61

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests — Prolaris® Prostate Cancer Test and MyRisk® Hereditary Cancer Test – into Lumea’s digital pathology platform, BxLink™. This collaboration will...Read more


Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

February 3
Last Trade: 3.10 -0.09 -2.82

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific immunity against multiple cancer types. CAPTN-3 antibodies are designed to promote innate-like antitumor functions by NK and CD8 T cells, through conditional activation of the anti-CD3 arm at the TME, blockade of NKG2A, and targeting tumor-specific antigens, potentially...Read more


KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology

January 30
Last Trade: 4.37 -0.38 -8.00

MAHWAH, N.J. / Jan 30, 2025 / Business Wire / KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical manufacturer on a Phase III clinical trial for an expanded indication of a...Read more


Cognizant and Gilead Sciences Expand Partnership to Drive Greater Value Through Advanced Technology Applications

January 30
Last Trade: 104.08 -1.88 -1.77

Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening diseases....Read more


ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

January 29
Last Trade: 3.62 0.30 9.04

Confirmatory trial builds on results of QUILT 3.055, a Phase 2 trial demonstrating ANKTIVA rescued T cells and activity of checkpoint inhibitors (CPIs) in patients with non-small cell lung cancer (NSCLC), who progressed on CPI therapies QUILT 3.055 showed prolonged overall survival in these second- and third-line NSCLC patients exceeding historical survival rates following chemotherapy ImmunityBio anticipates submitting a biologics...Read more


Rapid Dose Therapeutics Advances Collaboration with Global Leader for Market-Ready QuickStrip(R) Nicotine in 2025

January 28
Last Trade: 0.19 0.00 0.00

Burlington, Ontario--(Newsfile Corp. - January 28, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (RDT), a Canadian biotechnology company working with an international company in oral nicotine products, is pleased to announce the expansion of their collaboration through the continuation of the exclusive pre-commercialization agreement. This agreement aims to finalize the development of innovative, market-ready products projected for...Read more


Knight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for Onicit®

January 28
Last Trade: 5.64 0.07 1.26

MONTREAL and LUGANO, Switzerland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced that Knight, through one of its...Read more


Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions

January 28
Last Trade: 2.55 0.18 7.59

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the strengthening of its foothold throughout Europe and the Middle East through its partnership with IVY Diagnostics Srl (“IVY Diagnostics”). As a key distributor, IVY Diagnostics is playing an integral role in...Read more


Quantum-Si and IDEX Health & Science to Partner on Optics Module for Proteus™ Instrument

January 28
Last Trade: 1.96 -0.07 -3.45

BRANFORD, Conn. / Jan 28, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and IDEX Health & Science, LLC., today announced they will partner on the development and manufacturing of the optics module for Quantum-Si’s novel proteomics platform, Proteus™. IDEX Health & Science, LLC is the global leader in life science optics, fluidics and...Read more


Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

January 27
Last Trade: 30.42 -1.49 -4.67

NASHVILLE, Tenn. / Jan 27, 2025 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora (NYSE: COR). Harrow Cares delivers a comprehensive suite of high‑quality access and affordability services, enhancing support for retina specialists, their staff, and patients. Through a state-of-the-art patient...Read more


Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration With Yuwell

January 26
Last Trade: 10.64 -0.02 -0.19

GOLETA, Calif. / Jan 26, 2025 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has entered into a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ, “Yuwell”), a global home healthcare medical device manufacturer with a comprehensive portfolio of respiratory products. The...Read more


Veeva Systems and Zifo Partner to Accelerate Quality Control Modernization

January 23
Last Trade: 234.00 -0.15 -0.06

Integration will reduce the burden of master lab data configuration, lowering costs and speeding Veeva LIMS implementation PLEASANTON, Calif. and DEERFIELD, Ill., Jan. 23, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and Zifo today announced a product partnership to help biopharmas modernize quality control (QC) operations. By bringing together Veeva LIMS with Zifo's data integration and management platform, qcKen, companies can...Read more


Becton Dickinson and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development

January 23
Last Trade: 224.80 -0.21 -0.09

FRANKLIN LAKES, N.J. & SAN DIEGO / Jan 23, 2025 / Business Wire / BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, today announced a framework collaboration agreement to enable and facilitate robotic arm integration with BD flow cytometry instruments to accelerate drug discovery and...Read more


AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology

January 23
Last Trade: 192.87 13.67 7.63

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license...Read more


Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline

January 22
Last Trade: 1.68 0.05 3.07

Award-winning Agility Life Sciences brings a proven track record in drug formulation for a number of pharmaceutical and biotechnology clients. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced that it has entered into a strategic services agreement with formulation development CDMO Agility Life Sciences (“Agility”) to...Read more


Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements

January 22
Last Trade: 36.54 -0.47 -1.27

Industry partners to provide funding and data to support ACAT™ model improvements RESEARCH TRIANGLE, N.C. / Jan 22, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies...Read more


The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

January 21
Last Trade: 3.59 -0.01 -0.28

Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va., Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to...Read more


Dermata Therapeutics and Revance Therapeutics Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

January 21
Last Trade: 1.19 0.06 5.31

The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis  If successful, the Companies may explore clinical development in additional indications  Xyngari™ with Daxxify® has the potential to be the first approved needle-free intradermal delivery of a botulinum toxin product  SAN DIEGO, CA and SOUTH SAN FRANCISCO, CA / ACCESS...Read more


CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

January 21
Last Trade: 10.48 0.04 0.38

BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other...Read more


Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line

January 17
Last Trade: 0.90 -0.01 -1.23

RA'ANANA, ISRAEL, Jan. 17, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced that the Company is establishing a dedicated production line for a crucial component of its innovative respiratory support system, in collaboration with Zriha Medical Ltd ("Zriha Medical"), a leading international manufacturer specializing in...Read more


Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

January 16
Last Trade: 48.12 1.14 2.43

Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types Longitudinal DNA methylation measurements and comprehensive genomic profiling allow deeper insights into intrinsic and acquired resistance mechanisms PALO ALTO, Calif., & CAMBRIDGE, Mass. / Jan 16, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,...Read more


Charles River Laboratories and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

January 16
Last Trade: 151.99 -1.18 -0.77

WILMINGTON, Mass. / Jan 16, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron’s Closed System Solutions (CSS)™ line of liquid cytokines produced under current good manufacturing practices (CGMP) onto Charles River’s Cell Therapy Flex Platform for Process Development....Read more


Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

January 15
Last Trade: 9.47 0.00 0.00

Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance First program member is Segal Trials, a preferred provider for leading pharmaceutical companies globally Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in...Read more


University of California San Francisco and GE HealthCare Launch a Joint Research Program to Drive Innovations in Imaging, Brain Health and Precision Oncology

January 15
Last Trade: 92.21 -1.27 -1.36

New joint research program combines UCSF’s advanced clinical and research teams with GE HealthCare’s technical and engineering expertise to develop solutions that directly impact patient care. The collaboration aims to address two of the most prevalent disease states worldwide, neurodegenerative disease and cancer, by increasing accessibility of imaging, driving clinical impact and translating techniques to diagnose and treat these...Read more


Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

January 15
Last Trade: 2.04 0.02 0.75

Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products Second project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VRE) MELBOURNE, Australia, Jan. 15, 2025 (GLOBE NEWSWIRE) --  Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and...Read more


Sutter Health and GE HealthCare enter strategic partnership to benefit patients, physicians and clinicians with advanced, AI-powered imaging

January 14
Last Trade: 92.21 -1.27 -1.36

The multi-year collaboration enables expanded access to quality diagnostic care for patients in California and provides Sutter physicians and clinicians with access to technology advances and innovations. It will also drive ongoing, comprehensive training and education, fostering future healthcare professionals representing the diverse communities they serve. Sutter Health, one of the top integrated health delivery systems in the country...Read more


DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets

January 14
Last Trade: 0.70 0.05 7.71

New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels NEW YORK, Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a...Read more


Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

January 14
Last Trade: 8.60 0.08 0.94

SEATTLE and FORT MYERS, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (Nasdaq:NEO), a leading oncology testing services company, today announced a multi-year exclusive strategic commercial collaboration that will...Read more


Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

January 14
Last Trade: 12.38 0.08 0.65

STAFFORD, Texas, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of clinical sites in Germany. The Company has partnered with GBG (German Breast Group), the largest academic breast...Read more


IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions

January 13
Last Trade: 193.44 -2.61 -1.33

RESEARCH TRIANGLE PARK, N.C. / Jan 13, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences. The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered...Read more


Illumina and NVIDIA collaborate to decode biology and propel precision health

January 13
Last Trade: 102.45 0.67 0.66

Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in...Read more


AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

January 13
Last Trade: 3.27 0.24 7.92

VANCOUVER, British Columbia / Jan 13, 2025 / Business Wire / AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion builds upon the successful partnership established in December 2022 and includes access to AbCellera’s TCE platform to develop therapeutic antibodies for tumor targets. “We are pleased...Read more


AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

January 13
Last Trade: 192.87 13.67 7.63

NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a humanized...Read more


Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI

January 13
Last Trade: 0.16 -0.01 -5.88

VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the successful achievement of a shortlist of AI-generated molecules targeting ATR (Ataxia Telangiectasia and Rad3-related protein) with specific designs for central nervous system (CNS)...Read more


Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

January 13
Last Trade: 112.26 -0.62 -0.55

WALTHAM, Mass. & SAN DIEGO / Jan 13, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated...Read more


Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

January 13
Last Trade: 14.73 1.18 8.71

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON, Jan. 13, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation...Read more


Progyny: Cigna Healthcare Expands Access to Fertility and Family-Building Benefits and Services

January 13
Last Trade: 22.36 0.41 1.87

BLOOMFIELD, Conn., Jan. 13, 2025 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), today announced a new offering in collaboration with Progyny, Inc (Nasdaq: PGNY) that makes best-in-class fertility and family-building services accessible and equitable for more employers. This new and comprehensive benefit will enable employers to offer expanded coverage throughout the entire fertility journey,...Read more


Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France 

January 13
Last Trade: 12.38 0.08 0.65

STAFFORD, Texas, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the activation of clinical sites in France. According to the latest data collected by the European Cancer Information System (click...Read more


Regeneron Pharmaceuticals Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

January 13
Last Trade: 673.60 -0.67 -0.10

The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project Extensively expanded database effort is designed to dramatically accelerate...Read more


Teva Pharmaceutical Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

January 13
Last Trade: 16.25 -0.38 -2.29

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1 Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis®2 (ranibizumab) in Europe The partnership broadens Teva's biosimilars portfolio, in line with its Pivot to Growth strategy TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE)...Read more


Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

January 12
Last Trade: 40.00 -0.30 -0.74

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus’ leading Biclonics® technology platform, and Biohaven’s next-generation ADC conjugation and payload platform...Read more


Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

January 12
Last Trade: 4.81 -0.11 -2.24

New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to ten Expanded partnership highlights the parties’ emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med’s expertise in the development of 212Pb-based TAT and vast proprietary supply of 212Pb and Molecular Partners’ unique Radio-DARPins as an ideal vector for...Read more


Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

January 10
Last Trade: 5.83 3.06 110.43

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the...Read more


PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

January 10
Last Trade: 1.84 0.36 24.32

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered...Read more


Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

January 9
Last Trade: 29.00 0.18 0.62

SHANGHAI & SUZHOU, China & CAMBRIDGE, Mass. / Jan 09, 2025 / Business Wire / Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Through this...Read more


Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

January 9
Last Trade: 89.50 5.75 6.87

CHICAGO / Jan 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient...Read more


Tempus AI Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

January 8
Last Trade: 89.50 5.75 6.87

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical care for cancer patients is hindered by insufficient biomarkers...Read more


Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

January 8
Last Trade: 77.93 -0.90 -1.14

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular disease Expanded collaboration includes near-term payments totalling up to 190 million US dollars, while Valo is eligible to receive milestone payments of approximately 4.6 billion dollars, plus R&D funding and potential royalty...Read more


Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

January 8
Last Trade: 5.83 3.06 110.43

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. AMD will also make a $20 million investment in Absci, structured as a private investment in...Read more


Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems

January 7
Last Trade: 33.47 0.86 2.64

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems. The research collaboration will rely on the UVA Center for Diabetes...Read more


MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

January 7
Last Trade: 1.89 0.02 1.07

Phase 2 pivotal trials to evaluate efficacy of THIO in combination with BeiGene’s checkpoint inhibitor (CPI) tislelizumab CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into a clinical supply agreement with global oncology company BeiGene to assess the...Read more


Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

January 7
Last Trade: 1.79 0.05 2.87

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta), Sutro’s Tubulin FRα-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer and other FRα...Read more


MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

January 7
Last Trade: 14.56 -0.09 -0.61

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research...Read more


Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

January 7
Last Trade: 459.00 -3.58 -0.77

Collaboration to leverage Orna's differentiated lipid nanoparticle (LNP) delivery solutions for patients with SCD and TDT  Orna to receive an upfront payment and is eligible to receive potential pre-clinical, clinical, and commercialization milestone payments and royalties  WATERTOWN, Mass., Jan. 7, 2025 /PRNewswire/ -- Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a...Read more


iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

January 7
Last Trade: 3.43 -0.17 -4.72

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio’s patented Machine-Learning Antibody Engine. Developing an antibody against Activin E, a...Read more


Exicure Partners with GPCR Therapeutics to Fuel New Growth in Biotech

December 26
Last Trade: 9.80 -0.29 -2.87

CHICAGO / Dec 26, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (“GPCR Therapeutics”) on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR Therapeutics’ ongoing drug development pipelines. Through this...Read more


Voyageur Pharmaceuticals Signs Letter of Intent with Global Contrast Imaging Company to Expand Market Reach and Product Portfolio

December 20
Last Trade: 0.18 0.00 0.00

LOI Agreement is steppingstone to formal agreement,  The Multinational Pharmaceutical company is ranked in the top five contrast agent suppliers in the world, signaling and solidifying Voyageur’s importance in the global contrast agent market  Calgary, Alberta, Canada – TheNewswire - December 20, 2024 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") a vertically integrated...Read more


Renovaro Enters into Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

December 20
Last Trade: 0.81 0.07 9.03

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic...Read more


Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

December 19
Last Trade: 5.51 0.52 10.42

FREMONT, Calif. / Dec 19, 2024 / Business Wire / Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and...Read more


Prenetics Global IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

December 19
Last Trade: 5.41 0.32 6.29

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics’ (NASDAQ:PRE) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to...Read more


Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

December 19
Last Trade: 1.46 0.10 7.35

Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnership with VITALExam LLC...Read more


Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters

December 19
Last Trade: 2.78 0.22 8.59

BOSTON / Dec 19, 2024 / Business Wire / Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling. In the field of...Read more


BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

December 18
Last Trade: 4.79 0.27 5.97

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) --...Read more


Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

December 18
Last Trade: 48.12 1.14 2.43

PALO ALTO, Calif. / Dec 18, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing epidermal...Read more


DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

December 18
Last Trade: 5.54 -0.02 -0.36

NEW YORK / Dec 18, 2024 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced an expanded partnership with SHL Telemedicine (NASDAQ: SHLT) to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. This expanded collaboration, initially launched in the New York-New Jersey area, will now bring advanced...Read more


Gilead Sciences and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

December 17
Last Trade: 104.08 -1.88 -1.77

Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest  Gilead Has Exclusive Option to Develop and Commercialize Products from the Collaboration  FOSTER CITY, Calif. & LOS ANGELES / Dec 17, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a...Read more


EUDA Health and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation

December 16
Last Trade: 4.19 0.09 2.29

Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”), a...Read more


Clearmind Medicine and Dr Glitter Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

December 16
Last Trade: 1.41 0.01 0.71

The term sheet is non-binding, subject to the execution of a definitive agreement  Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has signed a non-binding term...Read more


Personalis and Tempus Expand Collaboration to Biopharma

December 16
Last Trade: 5.51 0.52 10.42

Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution FREMONT, Calif. / Dec 16, 2024 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of...Read more


Forian Partners With Databricks to Expand Access to Advanced Healthcare Analytics

December 16
Last Trade: 3.60 0.84 30.43

NEWTOWN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Forian Inc. (Nasdaq: FORA), a leading provider of data science driven information and analytics solutions to the life science, healthcare and financial services industries, today announced a partnership with Databricks, the data and AI company, to deliver access to its Chartis™ product, which maps physician and organization affiliations, through Databricks Marketplace. This collaboration...Read more


Spectral AI Highlights Unprecedented Collaboration with National Leaders in Burn Care for DeepView™ System Training and Validation Studies

December 12
Last Trade: 2.12 -0.05 -2.30

DALLAS, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced that national leaders in burn care have dedicated more than an estimated 511 in-person days of physician engagement to...Read more


CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

December 11
Last Trade: 24.50 -0.34 -1.37

CareDx Continues Strategic Expansion into Hematology Oncology with Pharmacokinetic and Monitoring Assays for Cell Therapy Patients BRISBANE, Calif. / Dec 11, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers –...Read more


TC Biopharm Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

December 11
Last Trade: 2.45 -0.008 -0.33

EDINBURGH, Scotland, Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant Company™ who will perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE